Related references
Note: Only part of the references are listed.Molecular features of aggressive thyroid cancer
Giusy Elia et al.
FRONTIERS IN ONCOLOGY (2022)
Preclinical Therapeutic Evaluation of Lenvatinib-Eluting Microspheres for Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma
Jason Pe et al.
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY (2022)
Cell-cycle and apoptosis related and proteomics-based signaling pathways of human hepatoma Huh-7 cells treated by three currently used multi-RTK inhibitors
Xuejiao Ren et al.
FRONTIERS IN PHARMACOLOGY (2022)
STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib
Yahui Zheng et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Clinical efficacy of lenvatinib for the treatment of radioiodine-refractory thyroid carcinoma: A systematic review and meta-analysis of clinical trials
Zhipeng Yan et al.
CLINICAL ENDOCRINOLOGY (2021)
EGFR Targeted Cetuximab-Valine-Citrulline (vc)-Doxorubicin Immunoconjugates-Loaded Bovine Serum Albumin (BSA) Nanoparticles for Colorectal Tumor Therapy
Zixuan Ye et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2021)
Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors
Lisa Agnello et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Novel treatments for anaplastic thyroid carcinoma
Silvia Martina Ferrari et al.
GLAND SURGERY (2020)
Enhanced antitumor efficacy in colon cancer using EGF functionalized PLGA nanoparticles loaded with 5-Fluorouracil and perfluorocarbon
Pingping Wu et al.
BMC CANCER (2020)
Cetuximab conjugated temozolomide-loaded poly (lactic-co-glycolic acid) nanoparticles for targeted nanomedicine in EGFR overexpressing cancer cells
Ramesh Duwa et al.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY (2020)
Lenvatinib and pembrolizumab in advanced gastric cancer
Stefano Cascinu
LANCET ONCOLOGY (2020)
Cetuximab-conjugated perfluorohexane/gold nanoparticles for low intensity focused ultrasound diagnosis ablation of thyroid cancer treatment
Ying Liu et al.
SCIENCE AND TECHNOLOGY OF ADVANCED MATERIALS (2020)
Post-Translational Modifications of Cytochrome c in Cell Life and Disease
Alejandra Guerra-Castellano et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy
Jing Jin et al.
FRONTIERS IN ONCOLOGY (2019)
Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy
L. D. Locati et al.
EUROPEAN JOURNAL OF CANCER (2019)
Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies
Mohamed Aashiq et al.
CANCERS (2019)
Anaplastic Thyroid Cancer: Clinical Picture of the Last Two Decades at a Single Oncology Referral Centre and Novel Therapeutic Options
Joana Simoes-Pereira et al.
CANCERS (2019)
Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer
Maria E. Cabanillas et al.
SEMINARS IN ONCOLOGY (2019)
Evaluation of the scars' vascularization using computer processing of the digital images
Valerii Teplyi et al.
SKIN RESEARCH AND TECHNOLOGY (2019)
Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models
Masahiro Matsuki et al.
CANCER MEDICINE (2018)
PLGA-Based Nanoparticles in Cancer Treatment
Sima Rezvantalab et al.
FRONTIERS IN PHARMACOLOGY (2018)
Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration
Silvia Martina Ferrari et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Lenvatinib: Role in thyroid cancer and other solid tumors
Maria E. Cabanillas et al.
CANCER TREATMENT REVIEWS (2016)
Nanoparticles for oral delivery: Design, evaluation and state-of-the-art
Abhijit A. Date et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer
Loredana Lorusso et al.
ONCOTARGETS AND THERAPY (2016)
Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis
Chenjing Zhu et al.
ONCOTARGET (2016)
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Edgar Perez-Herrero et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2015)
SELECT—lenvatinib in thyroid cancer
David Killock
Nature Reviews Clinical Oncology (2015)
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Martin Schlumberger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer
Francis Worden
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2014)
Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
Osamu Tohyama et al.
JOURNAL OF THYROID RESEARCH (2014)
Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma
Kevin E. Fisher et al.
JOURNAL OF SURGICAL RESEARCH (2013)
NIH Image to ImageJ: 25 years of image analysis
Caroline A. Schneider et al.
NATURE METHODS (2012)
The Impact of Distant Metastases at Presentation on Prognosis in Patients with Differentiated Carcinoma of the Thyroid Gland
Iain J. Nixon et al.
THYROID (2012)
The Double Edged Sword of Bleeding and Clotting from VEGF Inhibition in Renal Cancer Patients
Guru Sonpavde et al.
CURRENT ONCOLOGY REPORTS (2012)
Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor
Yung-Chih Kuo et al.
BIOMATERIALS (2011)
AIF promotes chromatinolysis and caspase-independent programmed necrosis by interacting with histone H2AX
Cedric Artus et al.
EMBO JOURNAL (2010)
Share Paper
